Silbermann M H, Boersma A W, Janssen A L, Scheper R J, Herweijer H, Nooter K
Radiobiological Institute TNO, Rijswijk, The Netherlands.
Int J Cancer. 1989 Oct 15;44(4):722-6. doi: 10.1002/ijc.2910440428.
Multidrug-resistance (MDR) is characterized by the presence of a 170 kDa glycoprotein (P-glycoprotein) in the plasma membrane. P-glycoprotein is thought to act as an efflux pump, leading to reduced drug accumulation in MDR cells. This defect in drug accumulation can be overcome by membrane transport modulating agents (MTMAs). We determined the concentration of MTMA needed for maximal restoration of daunorubicin content in 4 Chinese hamster ovary cell lines with increasing levels of drug-resistance using flow cytometry. Stimulation of daunorubicin accumulation occurred in a dose-dependent manner. The required level of MTMA needed for maximal drug accumulation increased with the level of drug-resistance. CHrA3 cells, which have a level of resistance comparable to clinical samples, needed relatively low concentrations of MTMA for maximal restoration of drug accumulation. This indicates that, in trial combining drugs and MTMAs, low dosages of MTMAs could be sufficient for optimal potentiation of cytotoxicity.
多药耐药性(MDR)的特征是质膜中存在一种170 kDa的糖蛋白(P-糖蛋白)。P-糖蛋白被认为起着外排泵的作用,导致多药耐药细胞中药物积累减少。膜转运调节剂(MTMAs)可以克服这种药物积累缺陷。我们使用流式细胞术测定了在4种耐药性水平不断增加的中国仓鼠卵巢细胞系中,使柔红霉素含量最大程度恢复所需的MTMA浓度。柔红霉素积累的刺激呈剂量依赖性。最大药物积累所需的MTMA水平随耐药性水平的增加而增加。具有与临床样本相当耐药水平的CHrA3细胞,最大程度恢复药物积累所需的MTMA浓度相对较低。这表明,在联合使用药物和MTMAs的试验中,低剂量的MTMAs可能足以实现细胞毒性的最佳增强。